Wang Weihua, Yellamsetty Anusha, Edmonds Robert M, Barcavage Shaun R, Bao Shaowen
Department of Physiology and Department of Otolaryngology-Head and Neck Surgery, University of Arizona College of Medicine, Tucson, AZ, United States.
Department of Audiology, College of Health and Human Sciences, San José State University, San José, CA, United States.
Front Pharmacol. 2024 May 22;15:1374320. doi: 10.3389/fphar.2024.1374320. eCollection 2024.
Cases of tinnitus have been reported following administration of COVID-19 vaccines. The aim of this study was to characterize COVID-19 vaccination-related tinnitus to assess whether there is a causal relationship, and to examine potential risk factors for COVID-19 vaccination-related tinnitus. We analyzed a survey on 398 cases of COVID-19 vaccination-related tinnitus, and 699,839 COVID-19 vaccine-related reports in the Vaccine Adverse Effect Reporting System (VAERS) database that was retrieved on 4 December 2021. We found that following COVID-19 vaccination, 1) tinnitus report frequencies for Pfizer, Moderna and Janssen vaccines in VAERS are 47, 51 and 70 cases per million full vaccination; 2) the symptom onset was often rapid; 3) more women than men reported tinnitus and the sex difference increased with age; 4) for 2-dose vaccines, the frequency of tinnitus was higher following the first dose than the second dose; 5) for 2-dose vaccines, the chance of worsening tinnitus symptoms after second dose was approximately 50%; 6) tinnitus was correlated with other neurological and psychiatric symptoms; 7) pre-existing metabolic syndromes were correlated with the severity of the reported tinnitus. These findings suggest that COVID-19 vaccination increases the risk of tinnitus, and metabolic disorders is a risk factor for COVID-19 vaccination-related tinnitus.
有报告称接种新冠疫苗后出现耳鸣病例。本研究的目的是对与新冠疫苗接种相关的耳鸣进行特征描述,以评估是否存在因果关系,并研究与新冠疫苗接种相关耳鸣的潜在风险因素。我们分析了一项针对398例与新冠疫苗接种相关耳鸣病例的调查,以及2021年12月4日从疫苗不良反应报告系统(VAERS)数据库中检索到的699,839份与新冠疫苗相关的报告。我们发现,接种新冠疫苗后,1)VAERS中辉瑞、莫德纳和杨森疫苗的耳鸣报告频率分别为每百万次全程接种47例、51例和70例;2)症状发作通常很快;3)报告耳鸣的女性多于男性,且性别差异随年龄增加而增大;4)对于两剂次疫苗,第一剂后耳鸣频率高于第二剂;5)对于两剂次疫苗,第二剂后耳鸣症状加重的几率约为50%;6)耳鸣与其他神经和精神症状相关;7)既往存在的代谢综合征与报告的耳鸣严重程度相关。这些发现表明,接种新冠疫苗会增加耳鸣风险,代谢紊乱是与新冠疫苗接种相关耳鸣的一个风险因素。